Login to Your Account

Total funding for CRISPR contenders tops $1B as Crispr Therapeutics prices $56M IPO

By Cormac Sheridan
Staff Writer

Wednesday, October 19, 2016

DUBLIN – Crispr Therapeutics AG pulled in $56 million in an IPO on Nasdaq, alongside a concurrent private placement with strategic partner Bayer AG, which raised another $35 million. The combined transactions take the company’s total funding raised from inception to $384.4 million, including private and public equity investment, convertible loans and collaboration revenues.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription